Iniciar sesión Regístrese gratis

Last updated: 5 November 2021 at 9:44am EST

Tae Heum Jeong Net Worth



Mr. Jeong NRBO stock SEC Form 4 insiders trading

Tae has made over 3 trades of the NeuroBo Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 317,272 units of NRBO stock worth $253,818 on 8 January 2015.

The largest trade he's ever made was exercising 317,272 units of NeuroBo Pharmaceuticals Inc stock on 8 January 2015 worth over $253,818. On average, Tae trades about 60,350 units every 37 days since 2013. As of 8 January 2015 he still owns at least 554,800 units of NeuroBo Pharmaceuticals Inc stock.

You can see the complete history of Mr. Jeong stock trades at the bottom of the page.





Tae Heum Jeong biography

Tae Heum Jeong serves as Independent Director of the Company. He has served as Managing Partner at Kensington-SV Global Innovations, L.P., a transformative innovation-focused venture capital fund targeting early and growth-stage companies primarily in the United States and Korea since 2018. From 2002 through 2018, Dr. Jeong served in various roles of progressive responsibility at Rexahn Pharmaceuticals, Inc. (Nasdaq: REXN), including Chief Financial Officer and Board Director, where he played key roles in the company's business development, private placement, underwritten and registered direct public offerings. From 1997 until 2002, Dr. Jeong served as Senior Investment Manager at Hyundai Venture Investment Corporation, a subsidiary of Hyundai Motors conglomerate and one of the largest venture capital firms in South Korea, where he specialized in venture capital investments in the healthcare industry and assisted in taking numerous companies public. Dr. Jeong holds a BS and MS in Chemistry from Pohang University of Science and Technology in Pohang, South Korea, an MS in Finance from Johns Hopkins University, and a Doctor of Management from the University of Maryland, University College. Our Board believes that Dr. Jeong's substantial public company finance experience will assist the Company in its public reporting and funding activities as we grow and develop and qualifies him to serve as a director.



How old is Tae Jeong?

Tae Jeong is 49, he's been the Independent Director of NeuroBo Pharmaceuticals Inc since 2019. There are 5 older and 6 younger executives at NeuroBo Pharmaceuticals Inc. The oldest executive at NeuroBo Pharmaceuticals Inc is Michael Salsbury, 70, who is the Independent Director.

What's Tae Jeong's mailing address?

Tae's mailing address filed with the SEC is 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY, UT, 84121.

Insiders trading at NeuroBo Pharmaceuticals Inc

Over the last 5 years, insiders at NeuroBo Pharmaceuticals Inc have traded over $0 worth of NeuroBo Pharmaceuticals Inc stock and bought 2,544,530 units worth $7,964,379 . The most active insiders traders include St Co., Ltd Dong A, Tae Heum Jeong y Steven R. Ph.D. Gullans. On average, NeuroBo Pharmaceuticals Inc executives and independent directors trade stock every 0 days with the average trade being worth of $9,541,988. The most recent stock trade was executed by St Co., Ltd Dong A on 23 June 2024, trading 2,544,530 units of NRBO stock currently worth $7,964,379.



What does NeuroBo Pharmaceuticals Inc do?

neurobo pharmaceuticals, inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. its therapeutics programs include nb-01 for the treatment of painful diabetic neuropathy; nb-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and gemcabene, which is focused on developing and commercializing therapies for the treatment of dyslipidemia. neurobo pharmaceuticals, inc. was incorporated in 2017 and is headquartered in boston, massachusetts.



What does NeuroBo Pharmaceuticals Inc's logo look like?

NeuroBo Pharmaceuticals Inc logo

NeuroBo Pharmaceuticals Inc executives and stock owners

NeuroBo Pharmaceuticals Inc executives and other stock owners filed with the SEC include: